In this work, we have found an antiproliferative effect on Leishmania sp. promastigotes and axenic amastigotes by the human immunodeficiency virus (HIV) aspartyl-proteinase inhibitors, Ac-Leu-Val-Phenylalaninal, Saquinavir mesylate and Nelfinavir, the latter two being used as part of antiretroviral therapy. This effect appears to be the result of cell division blockage. In addition, these drugs induced in culture a decrease in the percentage of co-infected HIV/Leishmania monocytes and amastigotes of Leishmania per macrophage. The finding of a dose-dependent inhibition of Leishmania promastigotes aspartyl-proteinase activity by these drugs allows us to propose this activity as the drug parasite target. A direct action of these HIV aspartyl-proteinase inhibitors on the parasite, would be correlated with the effect that highly active antiretroviral therapy have had in the decrease of HIV/Leishmania coinfection, opening an interesting perspective for new drugs research development based on this novel parasite proteinase family.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.exppara.2010.06.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Structural and Functional Studies on HIV Protease: Mechanism of Action, Subtypes, Inhibitors, and Drug Resistance.
Methods Mol Biol
November 2024
Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai, Tamil Nadu, India.
Human immunodeficiency virus (HIV) targets the host immune system causing acquired immunodeficiency syndrome (AIDS). Although significant advancements have been made on investigating HIV and related infections, eradicating the virus from the host immune system is still challenging. Nevertheless, the combination therapies using drugs targeting different stages in the viral life cycle are used for treatment in which HIV protease plays a vital role.
View Article and Find Full Text PDFQuantum mechanical analysis of newly synthesized HIV-1 protease inhibitors: evaluation of wild-type and resistant strain binding interactions.
Phys Chem Chem Phys
October 2024
Departamento de Biofísica e Farmacologia, Universidade Federal do Rio Grande no Norte, 59072-970, Natal-RN, Brazil.
Inhibition of HIV-1 protease is a cornerstone of antiretroviral therapy. However, the notorious ability of HIV-1 to develop resistance to protease inhibitors (PIs), particularly darunavir (DRV), poses a major challenge. Using quantum chemistry and computer simulations, this study aims to investigate the interactions between two novel PIs, GRL-004 and GRL-063, as well as a wild-type (WT) HIV strain and a DRV-resistant mutant strain.
View Article and Find Full Text PDFImproving Predictive Efficacy for Drug Resistance in Novel HIV-1 Protease Inhibitors through Transfer Learning Mechanisms.
J Chem Inf Model
October 2024
Molecular Therapy Lab, Department of Pharmaceutical Chemistry, School of Pharmacy, Bahcesehir University, Istanbul 34353, Turkey.
Article Synopsis
- The human immunodeficiency virus (HIV) poses a serious global health issue due to its ability to quickly mutate and develop resistance to drugs.
- Recent research highlights the success of machine learning (ML) and deep learning (DL) in predicting which HIV strains will resist FDA-approved treatments, but expanding these models to consider both viral isolates and drug characteristics remains a challenge.
- A new framework called the drug-isolate-fold change (DIF) model has been proposed, utilizing advanced modeling techniques and pre-trained graph neural networks to improve predictions on drug resistance, achieving notable accuracy and demonstrating the value of incorporating detailed molecular representations.
Identification of steroidal cardenolides from Calotropis procera as novel HIV-1 PR inhibitors: A molecular docking & molecular dynamics simulation study.
Indian J Med Res
July 2024
Department of Zoology, Kakatiya University, Hanamkonda, Warangal, Telangana, India.
Background & objectives Despite advancements in antiretroviral therapy, drug-resistant strains of HIV (human immunodeficiency virus) remain a global health concern. Natural compounds from medicinal plants offer a promising avenue for developing new HIV-1 PR (protease) inhibitors. This study aimed to explore the potential of compounds derived from Calotropis procera, a medicinal plant, as inhibitors of HIV-1 PR.
View Article and Find Full Text PDFPerformance of an in-house multiplex PCR assay for HIV-1 drug resistance testing - A cheaper alternative.
J Virol Methods
December 2024
Department of Medical Virology, University of Pretoria, South Africa; National Health Laboratory Service-Tshwane Academic Division (NHLS-TAD), Tshwane, South Africa. Electronic address:
Background: Currently, most HIV drug resistance PCR assays amplify the protease-reverse transcriptase (PR-RT) fragment separately from the integrase (IN) fragment. The aim of this study was to develop a multiplex PCR assay that simultaneously amplifies PR-RT and IN fragments for HIV-1 drug-resistance testing.
Methods: The in-house multiplex PCR assay was evaluated on extracted total nucleic acids obtained from the National Health Laboratory Service (NHLS) and Lancet laboratories.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!